Effects of atorvastatin and rosuvastatin on antiplatelet activity of clopidogrel in elderly patients with acute coronary syndrome

Objective To compare the effects of atorvastatin and rosuvastatin on antiplatelet activity of clopidogrel in elderly patients with acute coronary syndrome (ACS)． Methods From April 2014 to February 2015, 102 hospitalized elderly patients with acute coronary syndrome were assessed, the patients were randomly divided into atorvastatin 20 mg/d treatment group (n=53) and rosuvastatin 10 mg/d treatment group (n=49)． They all received anti-platelet treatment including aspirin (100 mg/d) and clopidogrel (75 mg/d) for one week, platelet aggregation and thrombelastogram were measured． All patients were followed up for 3 months, and major adverse cardiac events (MACE) rate and adverse drug reaction between the two groups were compared． Results There were no statistical differences in platelet inhibition ratio induced by ADP (58．75±25．87 vs 60．88±31．42)%, platelet aggregation function (31．86±19．81 vs 24．87±19．20)%, MACE rate and adverse drug reaction between two groups (P> 0．05)． Conclusion Neither atorvastatin nor rosuvastatin attenuates the anti-platelet effects of clopidogrel during co-medication for elderly patients with acute coronary syndrome．